Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1a in relapsing-remitting multiple sclerosis.

L Blumhardt1

  • 1Division of Clinical Neurology, University of Nottingham.

Hospital Medicine (London, England : 1998)
|September 7, 1999
PubMed
Summary

Interferon beta-1a effectively treats relapsing-remitting multiple sclerosis. Higher, more frequent doses are necessary for optimal therapeutic benefits, as low weekly doses show limited effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Motor and somatosensory evoked potentials in hereditary spastic paraplegia.

Journal of neurology, neurosurgery, and psychiatry·1991
Same author

Gabapentin as an antiepileptic drug in man.

Journal of neurology, neurosurgery, and psychiatry·1987
Same author

Fits, faints and funny turns.

The Practitioner·1986
Same author

Proceedings: Paradoxical reversal of lateralization of the half-field pattern-evoked response with monopolar and bipolar electrode montages.

The Journal of physiology·1976
Same author

A paradox in the lateralisation of the visual evoked response.

Nature·1976

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon beta-1a is an established therapy for relapsing-remitting MS (RRMS).

Purpose of the Study:

  • To evaluate the efficacy of interferon beta-1a in managing RRMS.
  • To determine optimal dosing and administration frequency for interferon beta-1a therapy.

Main Methods:

  • Analysis of accumulated data from multiple clinical trials.
  • Assessment of both clinical outcomes and magnetic resonance imaging (MRI) endpoints.

Main Results:

  • Interferon beta-1a demonstrates significant benefits in reducing disease activity in RRMS.
  • Low doses of interferon beta-1a administered weekly appear to be less effective.
  • Higher and more frequent dosing regimens are associated with optimal patient benefits.

Conclusions:

  • Interferon beta-1a is a beneficial treatment for RRMS.
  • Dosing strategy is critical for maximizing the therapeutic effects of interferon beta-1a in MS patients.

Related Experiment Videos